Regression following reduction of the daily drug dosage in cyclosporin A-induced gingival overgrowth in bone marrow transplant recipients

Acta Stomatol Belg. 1993 Sep;90(3):171-6.

Abstract

This study was undertaken on 181 patients treated with bone marrow transplantation and in therapy with cyclosporin-A. 22 of the 181 (12.5%) exhibited a marked gingival overgrowth that covered more than 1/3 of crown length. The development of gingival overgrowth appeared in a range of 8 to 365 days, with a mean of 75 days, from the beginning of the immunosuppressive treatment with the drug. During the course of treatment, after a time period ranging from 30 to 365 days (mean 180 days), in 50% of the patients there was a total regression of the gingival pathology and in 36.4% a partial regression. It has not been possible to correlate the occurrence of gingival overgrowth with the presence of plaque or calculus and with the cumulative dosage of the drug. It is possible that a reduction in the daily drug dosage below a certain threshold may produce a partial or complete regression of the gingival pathology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Bone Marrow Transplantation*
  • Child
  • Child, Preschool
  • Cyclosporine / administration & dosage
  • Cyclosporine / adverse effects*
  • Cyclosporine / therapeutic use
  • Dental Care
  • Drug Administration Schedule
  • Gingival Hypertrophy / chemically induced*
  • Gingival Hypertrophy / classification
  • Humans
  • Infant
  • Middle Aged
  • Oral Hygiene

Substances

  • Cyclosporine